{"id":45627,"date":"2022-06-29T13:01:39","date_gmt":"2022-06-29T11:01:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/"},"modified":"2022-06-29T13:01:39","modified_gmt":"2022-06-29T11:01:39","slug":"harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/","title":{"rendered":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform"},"content":{"rendered":"
\n

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger\u2019s novel platform technology for blood-based early cancer detection.\n<\/p>\n

<\/a><\/p>\n

\nThe C<\/b>ancer OR<\/b>igin E<\/b>pigenetics- H<\/b>arbinger H<\/b>ealth (CORE-HH) study plans to enroll a diverse and representative population with and without cancer at up to 40 sites across the U.S. The study is being run by SCRI\u2019s contract research organization and has begun enrollment at sites affiliated with HCA Healthcare, SCRI\u2019s parent company.\n<\/p>\n

\nThe primary objectives of the case-control study are to further develop and validate the diagnostic accuracy of Harbinger\u2019s platform technology for the detection of early-stage cancer across multiple cancer types and to assess the ability to determine tumor location. The study, which is expected to read out in stages through 2023, is designed to advance Harbinger\u2019s product development strategy.\n<\/p>\n

\n\u201cWe are pleased to work with SCRI, a leading clinical research organization conducting community-based clinical trials, as we drive toward Harbinger\u2019s goal of enabling the detection of cancer at the earliest points of disease, well before current means of screening could find it and when it\u2019s possible to intervene with the greatest possibilities of success,\u201d said Stephen Hahn, MD, CEO of Harbinger Health. \u201cWe share a vision of a world where nearly all cancers can be identified before they are symptomatic or even visible with simple, highly accurate and reliable blood tests that are widely accessible, particularly to those who have traditionally been underserved in our healthcare system.\u201d\n<\/p>\n

\n\u201cImproving the ability to detect more cancers at earlier stages is important,\u201d said Howard A. \u201cSkip\u201d Burris III, MD, FACP, FACSO<\/a>, President & Chief Medical Officer, SCRI. \u201cBlood-based testing has emerged in recent years as a potential way to address this important need, and we are excited to partner with Harbinger Health to develop testing capabilities that should improve outcomes for cancer patients through earlier diagnosis.\u201d\n<\/p>\n

\nMore information on the CORE-HH study is available on www.clinicaltrials.gov<\/a> using the identifier NCT05435066.\n<\/p>\n

\nAbout Harbinger Health<\/b>\n<\/p>\n

\nHarbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020. Learn more about Harbinger by visiting www.harbinger-health.com<\/a> or following us on Twitter (@harbingerhealth) and LinkedIn.\n<\/p>\n

\nAbout Sarah Cannon Research Institute<\/b>\n<\/p>\n

\nSarah Cannon Research Institute (SCRI) is the research arm of HCA Healthcare\u2019s Cancer Institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world\u2019s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. A leader in drug development, SCRI has led more than 600 first-in-human clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies for more than a decade. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), Sarah Cannon Development Innovations.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/span><\/b>\n<\/p>\n

\nHarbinger Health
\n
Adam Silverstein
\n
Scient PR
\n
adam@scientpr.com<\/a>
917-697-9313\n<\/p>\n

\nSarah Cannon
\n
Rebecca Gelman
\n
rebecca.gelman@sarahcannon.com<\/a>
347-986-9577\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger\u2019s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45627","6":"format-standard","7":"category-industry"},"yoast_head":"\nHarbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger\u2019s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-29T11:01:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform\",\"datePublished\":\"2022-06-29T11:01:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/\"},\"wordCount\":660,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005273\\\/en\\\/1500134\\\/21\\\/HRBG_finallogo2022_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/\",\"name\":\"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005273\\\/en\\\/1500134\\\/21\\\/HRBG_finallogo2022_Color.jpg\",\"datePublished\":\"2022-06-29T11:01:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005273\\\/en\\\/1500134\\\/21\\\/HRBG_finallogo2022_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220629005273\\\/en\\\/1500134\\\/21\\\/HRBG_finallogo2022_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/","og_locale":"en_US","og_type":"article","og_title":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend","og_description":"CAMBRIDGE, Mass. & NASHVILLE, Tenn.–(BUSINESS WIRE)–Harbinger Health, a biotechnology company pioneering the detection of early cancer, and Sarah Cannon Research Institute (SCRI) announced today the initiation of a 10,000-participant clinical study designed to validate and further develop Harbinger\u2019s novel platform technology for blood-based early cancer detection. The Cancer ORigin Epigenetics- Harbinger Health (CORE-HH) study plans ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-29T11:01:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform","datePublished":"2022-06-29T11:01:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/"},"wordCount":660,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/","url":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/","name":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg","datePublished":"2022-06-29T11:01:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220629005273\/en\/1500134\/21\/HRBG_finallogo2022_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/harbinger-health-and-sarah-cannon-research-institute-launch-clinical-study-to-validate-and-advance-development-of-harbingers-novel-early-cancer-detection-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Harbinger Health and Sarah Cannon Research Institute Launch Clinical Study to Validate and Advance Development of Harbinger\u2019s Novel Early Cancer Detection Platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45627"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45627\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}